TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15277927

Group type: EXPERIMENTAL
Intervention: Epidural neostigmine 500 micrograms with sufentanil 10 micrograms
Number of subjects: 125

Group type: COMPARATOR
Intervention: Epidural sufentanil 20 micrograms
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Epidural neostigmine 250 micrograms with sufentanil 10 micrograms
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Epidural neostigmine 750 micrograms with sufentanil 10 micrograms
Number of subjects: 125
Study: 11574085

Group type: EXPERIMENTAL
Intervention: Blinded interviews
Number of subjects: 132

Group type: COMPARATOR
Intervention: Unblinded interviews
Number of subjects: 132
Study: 9762801

Group type: EXPERIMENTAL
Intervention: Mean dPoes,max/dt at the start of treadmill walks
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Mean dPoes,max/dt at the finish of treadmill walks
Number of subjects: 6
Study: 8736322

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate at 1 microgram/ml
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate at 10 micrograms/ml
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate at 100 micrograms/ml
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laser Doppler velocimetry
Number of subjects: 0

Group type: COMPARATOR
Intervention: Perfusion imager
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dia-Stron reflectance spectrophotometer
Number of subjects: 0
Study: 2037387

Group type: EXPERIMENTAL
Intervention: Combination of 5-FU and PP over protein-A sepharose (group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Combination of 5-FU and PP over sepharose (group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 5-FU alone (group C)
Number of subjects: 30
Study: 7247172

Group type: EXPERIMENTAL
Intervention: Intravenous succinylcholine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular succinylcholine
Number of subjects: 0
Study: 30625372

Group type: EXPERIMENTAL
Intervention: Strength training only
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Aerobic training only
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Combination (strength + aerobic) training
Number of subjects: 282
Study: 28489464

Group type: EXPERIMENTAL
Intervention: RDN by the EnligHTN™ multi-electrode system
Number of subjects: 15

Group type: COMPARATOR
Intervention: Medical treatment continued (control group)
Number of subjects: 15
Study: 24732784

Group type: EXPERIMENTAL
Intervention: Resistance training once a week (G1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resistance training twice a week (G2)
Number of subjects: 30
Study: 24980226

Group type: EXPERIMENTAL
Intervention: 10% lidocaine
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 2% prilocaine
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 200

Group type: COMPARATOR
Intervention: saline solution
Number of subjects: 200
Study: 22013957

Group type: EXPERIMENTAL
Intervention: Group-G: snack fortified with G-FOS (8 g)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Group-P: fermented-malted finger-millet pancake with soy coconut dip (534 mg calcium/serving)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Group-C: low calcium rice-flakes snack with calcium carbonate (540 mg)
Number of subjects: 61
Study: 20215461

Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (QW; 2 mg)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (QW; 2 mg) after switching from exenatide BID
Number of subjects: 258
Study: 18410607

Group type: EXPERIMENTAL
Intervention: FerX‐Ella antireflux stent (n = 22)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Ultraflex stent with proton pump inhibitors (n = 26)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups (FerX‐Ella and Ultraflex with PPI)
Number of subjects: 49
Study: 15835832

Group type: EXPERIMENTAL
Intervention: Lateral side port orientation
Number of subjects: 87

Group type: COMPARATOR
Intervention: Cephalad side port orientation
Number of subjects: 87

Group type: COMPARATOR
Intervention: Caudad side port orientation
Number of subjects: 87
Study: 12430779

Group type: EXPERIMENTAL
Intervention: Vitamin supplementation (0.6 mg folic acid, 0.8 mg B12, and 2.0 mg B6) for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vitamin supplementation
Number of subjects: 40
Study: 10347289

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastroplasty
Number of subjects: 68

Group type: COMPARATOR
Intervention: Open gastroplasty
Number of subjects: 68
Study: 8814371

Group type: EXPERIMENTAL
Intervention: 17 Gy in two fractions (F2)
Number of subjects: 509

Group type: COMPARATOR
Intervention: 39 Gy in 13 fractions (F13)
Number of subjects: 509
Study: 1330574

Group type: EXPERIMENTAL
Intervention: 10 mg enalapril + 25 mg hydrochlorothiazide
Number of subjects: 19

Group type: COMPARATOR
Intervention: 10 mg enalapril
Number of subjects: 19
Study: 3918684

Group type: EXPERIMENTAL
Intervention: Mestranol
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Mestranol and Placebo
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Long term hormone replacement (Mestranol)
Number of subjects: 88
Study: 31740866

Group type: EXPERIMENTAL
Intervention: 100% collagenated bone mix (Group A)
Number of subjects: 19

Group type: COMPARATOR
Intervention: 90% collagenated bone mix + 10% collagen gel (Group B)
Number of subjects: 19
Study: 29903826

Group type: EXPERIMENTAL
Intervention: Fluticasone/Salmeterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26999985

Group type: EXPERIMENTAL
Intervention: MDT‐MB with prednisolone 20 mg/day for 6 months followed by tapering by 5 mg/2 weeks in 7th and 8th month (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: MDT‐MB alone for 12 months (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MDT‐MB with prednisolone (Group A)
Number of subjects: 60
Study: 25164134

Group type: EXPERIMENTAL
Intervention: Interposed abdominal compression-cardiopulmonary resuscitation (IAC-CPR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional CPR
Number of subjects: 40
Study: 20932069

Group type: EXPERIMENTAL
Intervention: Intramuscular clodronic acid 100 mg once weekly (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intramuscular clodronic acid 200 mg every 2 weeks (group B)
Number of subjects: 60
Study: 19363970

Group type: EXPERIMENTAL
Intervention: Dual-cure composite (MultiCore Flow)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Resin-modified glass-ionomer cement (Fuji II LC)
Number of subjects: 50
Study: 17566842

Group type: EXPERIMENTAL
Intervention: Radiation therapy combined with hyperthermia (RT + HT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard radiation therapy alone (RT)
Number of subjects: 80
Study: 14684404

Group type: EXPERIMENTAL
Intervention: Erythorbic acid at molar ratio of 2:1 relative to iron
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Erythorbic acid at molar ratio of 4:1 relative to iron
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ascorbic acid at molar ratio of 4:1
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Erythorbic acid at molar ratio of 4:1
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no added enhancer)
Number of subjects: 10
Study: 11317959

Group type: EXPERIMENTAL
Intervention: Comparative evaluation of laboratory data and histopathology of the bone marrow
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histotopography and cytological appearance of megakaryopoiesis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up studies on prefibrotic IMF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical parameters (EPO level, thrombocytosis, LAP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bone marrow features (megakaryopoiesis, interstitial changes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential examinations for unclassifiable MPDs
Number of subjects: 0
Study: 8398496

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Gallopamil (50 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 2427837

Group type: EXPERIMENTAL
Intervention: Celiprolol 400 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Celiprolol 600 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Atenolol 100 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 29847509

Group type: EXPERIMENTAL
Intervention: Efavirenz-containing regimens
Number of subjects: 820

Group type: COMPARATOR
Intervention: Baseline plasma bilirubin concentration
Number of subjects: 820
Study: 27418968

Group type: COMPARATOR
Intervention: MDCO-216 (ApoA-1 Milano/POPC) infusion at doses ranging from 5 to 40 mg/kg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 24755132

Group type: EXPERIMENTAL
Intervention: AMOXIL® (reference formulation)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: AMOXI‐PED® (test formulation)
Number of subjects: 25
Study: 24079062

Group type: EXPERIMENTAL
Intervention: Wake up
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Caffeine (50 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 20386601

Group type: EXPERIMENTAL
Intervention: Educational program for reducing incidence of porcine cysticercosis; duration: 2-9 months (median 4 months); method: lingual examination and antigen ELISA.
Number of subjects: 784

Group type: COMPARATOR
Intervention: Control group data from 21 of the 42 villages; method: lingual examination.
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Sentinel pigs provided to 295 households; method: reassessment for cysticercosis incidence.
Number of subjects: 784
Study: 19033002

Group type: EXPERIMENTAL
Intervention: Higher loading and initial maintenance dose of clopidogrel (600 mg loading dose on day 1 followed by 150 mg once daily on days 2 to 7, followed by 75 mg once daily on days 8-30)
Number of subjects: 18000

Group type: EXPERIMENTAL
Intervention: High-dose ASA (300-325 mg daily)
Number of subjects: 18000

Group type: COMPARATOR
Intervention: Standard-dose regimen of clopidogrel (300 mg loading dose on day 1, followed by 75 mg once daily on days 2-30)
Number of subjects: 18000

Group type: COMPARATOR
Intervention: Low-dose ASA (75-100 mg daily)
Number of subjects: 18000

Group type: EXPERIMENTAL
Intervention: Higher loading and initial maintenance dose of clopidogrel
Number of subjects: 18000

Group type: EXPERIMENTAL
Intervention: High-dose ASA
Number of subjects: 18000

Group type: COMPARATOR
Intervention: Standard-dose regimen of clopidogrel
Number of subjects: 18000

Group type: COMPARATOR
Intervention: Low-dose ASA
Number of subjects: 18000
Study: 16126801

Group type: EXPERIMENTAL
Intervention: CTX‐I
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: CTX‐II
Number of subjects: 105
Study: 14568740

Group type: EXPERIMENTAL
Intervention: Neutralising antibodies positive periods
Number of subjects: 541

Group type: COMPARATOR
Intervention: Neutralising antibodies negative periods
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Antibody-negative at 12 months
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Presence of neutralising antibodies
Number of subjects: 541
Study: 10625721

Group type: EXPERIMENTAL
Intervention: Mild resuscitative hypothermia (32 to 34 degrees C core temperature) for at least 24 hours after cardiac arrest.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 27
Study: 9367476

Group type: EXPERIMENTAL
Intervention: 10 ppm inhaled nitric oxide
Number of subjects: 24

Group type: COMPARATOR
Intervention: 10 ppm inhaled nitric oxide (after 24 h of conventional therapy)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10 ppm inhaled nitric oxide (initial treatment)
Number of subjects: 24
Study: 1315121

Group type: EXPERIMENTAL
Intervention: Oat bran
Number of subjects: 84

Group type: COMPARATOR
Intervention: Wheat bran
Number of subjects: 84
Study: 2942707

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 210
Study: 28980293

Group type: EXPERIMENTAL
Intervention: DASH diet intervention (n = 69)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Standard recommendations (Control group, n = 62)
Number of subjects: 131
Study: 27632909

Group type: EXPERIMENTAL
Intervention: 90 g of salmon twice weekly
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 180 g of salmon twice weekly
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 270 g of salmon twice weekly
Number of subjects: 19
Study: 24684171

Group type: EXPERIMENTAL
Intervention: Pulse-Train stimulation within the pedicle track using a ball-Tipped probe and electromyography from lower limb muscles
Number of subjects: 71

Group type: COMPARATOR
Intervention: Direct screw stimulation and electromyogram response from intercostal, abdominal, or lower limb muscles
Number of subjects: 71
Study: 23921761

Group type: EXPERIMENTAL
Intervention: IV CITX (5‐fluorouracil 500 mg/m(2) weekly for 24 weeks, mitomycin‐C 8 mg/m(2) every 6 weeks × 4)
Number of subjects: 82

Group type: COMPARATOR
Intervention: PO CITX (uracil-ftorafur (UFT) 400‐600 mg/day for 12 months)
Number of subjects: 82
Study: 21345243

Group type: EXPERIMENTAL
Intervention: Nordic walking
Number of subjects: 67

Group type: COMPARATOR
Intervention: Low-intensity walking
Number of subjects: 67
Study: 20533217

Group type: EXPERIMENTAL
Intervention: Complex micronutrient supplement
Number of subjects: 106
Study: 16414385

Group type: EXPERIMENTAL
Intervention: BMT plus PTA
Number of subjects: 23

Group type: COMPARATOR
Intervention: BMT plus supervised exercise
Number of subjects: 23

Group type: COMPARATOR
Intervention: BMT alone
Number of subjects: 23
Study: 15250846

Group type: EXPERIMENTAL
Intervention: Fibre-containing sip feed (150 kcal, 2.0 g fibre per 100 ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fibre-free sip feed (control)
Number of subjects: 60
Study: 11240837

Group type: EXPERIMENTAL
Intervention: NP-based care (n = 193)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Housestaff care (n = 188)
Number of subjects: 381
Study: 9052293

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 200

Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 200
Study: 8379600

Group type: EXPERIMENTAL
Intervention: Combination therapy with zidovudine and didanosine
Number of subjects: 69

Group type: COMPARATOR
Intervention: Zidovudine alone (600 mg/d)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Zidovudine alone
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Combination regimens using the same zidovudine dose
Number of subjects: 69
Study: 2429818

Group type: EXPERIMENTAL
Intervention: Dextran 40
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: HES 200
Number of subjects: 24
Study: 28726086

Group type: EXPERIMENTAL
Intervention: Self-management intervention for depression
Number of subjects: 302

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Intervention group over time
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Patients whose depression remitted
Number of subjects: 302
Study: 26803356

Group type: EXPERIMENTAL
Intervention: Lispro insulin
Number of subjects: 108

Group type: COMPARATOR
Intervention: Recombinant regular human insulin (RHI)
Number of subjects: 108
Study: 24895799

Group type: EXPERIMENTAL
Intervention: Daikenchuto (DKT), 7.5 g/day, p.o.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (lactobacillus preparation, 3g/day, p.o.)
Number of subjects: 54
Study: 22935955

Group type: EXPERIMENTAL
Intervention: Marsh pharmacokinetic model
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Schnider pharmacokinetic model
Number of subjects: 90

Group type: COMPARATOR
Intervention: Both models
Number of subjects: 90
Study: 20697547

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy regimens including oxaliplatin, irinotecan, and 5-Fluorouracil (5-FU)
Number of subjects: 1700

Group type: COMPARATOR
Intervention: Combination chemotherapy regimens
Number of subjects: 1700
Study: 18664026

Group type: EXPERIMENTAL
Intervention: Methacholine challenge test
Number of subjects: 36

Group type: COMPARATOR
Intervention: Coronary atherosclerosis plaque volume
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Eosinophil counts
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lymphocyte counts
Number of subjects: 36
Study: 15884029

Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Chosen music
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Combination of relaxation and chosen music
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 167
Study: 12822543

Group type: EXPERIMENTAL
Intervention: Blatella germanica (Bg) bronchial challenge
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl solution) bronchial challenge
Number of subjects: 25
Study: 11798658

Group type: EXPERIMENTAL
Intervention: Perindopril (4mg qd)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Nifedipine (10 mg tid)
Number of subjects: 52
Study: 9177646

Group type: EXPERIMENTAL
Intervention: Directed feedback every two months in the form of mailed computer-generated summaries containing mean ratings and written comments.
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no feedback).
Number of subjects: 44
Study: 1929090

Group type: EXPERIMENTAL
Intervention: IAL left in situ
Number of subjects: 60

Group type: COMPARATOR
Intervention: IAL removed
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healon removed
Number of subjects: 60
Study: 6356899

Group type: EXPERIMENTAL
Intervention: Labetalol (median daily doses of 600 mg)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 74
Study: 30739001

Group type: EXPERIMENTAL
Intervention: 12‐month Peer‐Led, Empowerment‐based Approach to Self‐management Efforts in Diabetes (PLEASED) program with 12 weekly contacts in the first 3 months and 18 biweekly contacts over the last 9 months.
Number of subjects: 197

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 197
Study: 28361739

Group type: EXPERIMENTAL
Intervention: MCT high (>6 g/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MCT moderate (1-6 g/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: MCT low (<1 g/day)
Number of subjects: 30
Study: 26518479

Group type: EXPERIMENTAL
Intervention: Intravenous ω‐3 PUFA‐enriched lipid emulsion 20% infusion 7 mL/kg once a day for 2 days before surgery and postoperative day (POD) 0
Number of subjects: 40

Group type: COMPARATOR
Intervention: Glucose 5%
Number of subjects: 40
Study: 25003731

Group type: EXPERIMENTAL
Intervention: Animated cartoon‐aided teaching
Number of subjects: 80

Group type: COMPARATOR
Intervention: Oral presentation without demonstration
Number of subjects: 80
Study: 22661450

Group type: EXPERIMENTAL
Intervention: Proadrenomedullin (ProADM) testing combined with the REA-ICU score
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Proadrenomedullin (ProADM) value ≥ 1.8 nmol/L or assignment to REA-ICU risk classes III-IV
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Proadrenomedullin (ProADM)
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Proadrenomedullin (ProADM) combined with REA-ICU score
Number of subjects: 877
Study: 19542859

Group type: EXPERIMENTAL
Intervention: Closed suction drain (12G) placed in preperitoneal space, removed within 24 hours after operation.
Number of subjects: 929

Group type: COMPARATOR
Intervention: No drain used during TEP repair.
Number of subjects: 929
Study: 16679997

Group type: EXPERIMENTAL
Intervention: Carbohydrate (6%) supplementation (4 mL x kg(‐1) x 15 min(‐1))
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 15
Study: 14647983

Group type: EXPERIMENTAL
Intervention: Statistical parametric mapping (SPM)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Single‐photon emission tomography (SPET)
Number of subjects: 24
Study: 11683688

Group type: EXPERIMENTAL
Intervention: 6 mg oral tegaserod
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.6 mg intravenous tegaserod
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral and intravenous tegaserod
Number of subjects: 12
Study: 9149576

Group type: EXPERIMENTAL
Intervention: Thrombolysis for pulmonary embolism
Number of subjects: 312
Study: 7713201

Group type: EXPERIMENTAL
Intervention: 1.6 mg beclomethasone dipropionate (BDP)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: 2.0 mg fluticasone propionate (FP)
Number of subjects: 134
Study: 3372274

Group type: EXPERIMENTAL
Intervention: Pollenex BP-850 Automatic Sphygmomanometer (standard condition)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pollenex BP-850 Automatic Sphygmomanometer (silent condition)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hawkesley Random Zero Sphygmomanometer (comparison group)
Number of subjects: 80
Study: 31642607

Group type: COMPARATOR
Intervention: PF-05089771 alone
Number of subjects: 25

Group type: COMPARATOR
Intervention: PF-05089771 with pregabalin
Number of subjects: 25

Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 25

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 25
Study: 29871696

Group type: EXPERIMENTAL
Intervention: Strengthening routine data collection and data use activities; implementation of the WHO Safe Childbirth Checklist modified for preterm birth; PRONTO simulation training and mentoring; support of quality improvement teams.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Data strengthening and introduction of the modified checklist.
Number of subjects: 0
Study: 27642676

Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques (EFT)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 63
Study: 26344023

Group type: COMPARATOR
Intervention: 2011-2012 cohort
Number of subjects: 432

Group type: COMPARATOR
Intervention: 1997-1998 cohort
Number of subjects: 432